Inovio Pharmaceuticals Inc expected to post a loss of $1.10 a share - Earnings Preview

Inovio Pharmaceuticals

07/08/2024 02:56

* Inovio Pharmaceuticals Inc  INO.OQ   INO.O  is expected
to show
a fall in quarterly revenue when it reports  results on August 8
for the period ending June 30 2024
    * The San Diego California-based  company is expected to
report a
46.2% decrease in revenue to $121.5 thousand from $225.97
thousand a year ago, according to the mean estimate from 6
analysts, based on LSEG data.
    * ​LSEG's mean analyst estimate for Inovio Pharmaceuticals
Inc is
for a loss of 100 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 3 "strong buy" or "buy," 3
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Inovio
Pharmaceuticals Inc is $16.50​, above​ its last closing price
of $8.67. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Mar. 31 2024  -1.01       -1.00      -1.31     Missed  -30.6
 Dec. 31 2024  -1.42       -1.27      -1.12     Beat    11.6
 Sep. 30 2023  -1.50       -1.52      -1.56     Missed  -2.6​
 Jun. 30 2023  -1.81       -1.74      -1.56     Beat    10.3
 ​​Mar.        -1.76       -1.74      -1.92     Missed  -10.3
 31 2023                                                
 Dec. 31 2022  -2.01       -2.02      -2.52     Missed  -25​
 Sep. 30 2022  -3.56       -3.55      -1.80     Beat    49.3
 Jun. 30 2022  -3.72       -3.74      -5.52     Missed  -47.6
 This summary was machine generated August 7 at 01:56 GMT.  All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)